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LKB1 is a serine/threonine kinase that is highly conserved 
throughout evolution. Its activity is allosterically controlled by 
interactions with the scaffold protein MO25 and the pseudo­
kinase STRAD (Rajakulendran and Sicheri, 2010). LKB1 acts 
as a master kinase that phosphorylates 14 kinases within a shared 
consensus motif (Hardie and Alessi, 2013). Germline mutations 
in the LKB1 gene cause Peutz­Jeghers syndrome, which is 
associated with increased cancer risk (Hemminki et al., 1998; 
Jenne et al., 1998), and inactivating somatic LKB1 mutations are 
found in several sporadic cancers, including melanoma (Guldberg 
et al., 1999; Rowan et al., 1999). Moreover, evidence from 
mouse models points to a prominent role for LKB1 as a suppres­
sor of metastasis in lung cancer and melanoma (Ji et al., 2007; 
Liu et al., 2012).
The contribution of the different LKB1 substrates to tumor 
suppression is poorly understood, with the exception of AMP­
activated protein kinase (AMPK). AMPK is activated in an 
LKB1­dependent manner in metabolically stressed cells, and, 
in turn, phosphorylates key metabolic enzymes and transcrip­
tion factors, causing a shift from anabolic (ATP­consuming) to 
catabolic (ATP­producing) metabolism (Hardie and Alessi, 2013; 
Fig. 1). This represents a crucial cellular response to metabolic 
stress that arrests cell proliferation and biosynthesis of macro­
molecules to restore energy homeostasis. As part of this response, 
AMPK inhibits the nutrient/energy/redox sensor mTORC1, 
which controls protein synthesis. Unrestrained mTORC1 activ­
ity in the absence of LKB1­AMPK activity leads to continued 
Gradients of soluble attractants as well as extracellular 
matrix (ECM) proteins serve as cues for directional cell 
movement. Such “chemotaxis” and “haptotaxis” steers 
migration of cells during embryonic development, wound 
healing, and immune responses. In this issue, Chan 
et al. (2014. J. Cell Biol. http://dx.doi.org/10.1083/jcb 
.201404067) show that the tumor suppressor LKB1 con-
trols haptotaxis through the microtubule affinity-regulating 
kinase (MARK) family, one of the many substrates of the 
LKB1 master kinase. In the absence of this pathway, mela-
noma cells migrate irrespective of ECM gradients, which 
may explain the increased metastatic spread observed in 
LKB1-deficient tumors.
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translation of HIF1, a transcription factor that helps tumor 
cells to switch from mitochondrial oxidative metabolism to 
aerobic glycolysis, a process referred to as “the Warburg ef­
fect” (Vander Heiden et al., 2009). Thus, loss of LKB1­AMPK 
signaling allows cancer cells to disregard metabolic stress and 
continue proliferating.
In addition to its role in metabolism, LKB1 controls cell 
division orientation and polarity (Baas et al., 2004; Mirouse and 
Billaud, 2011). Several LKB1 substrates have been implicated 
in this process, but activation of AMPK may be the predomi­
nant pathway (Zhang et al., 2006; Lee et al., 2007; Zheng and 
Cantley, 2007). AMPK directly or indirectly phosphorylates the 
myosin II regulatory light chain, thereby activating the myosin II 
motor protein that drives actomyosin contractility, which is es­
sential for cell polarity (Lee et al., 2007). Consequently, loss 
of LKB1­AMPK activity not only allows cancer cells to rewire 
metabolic signaling networks but also causes loss of epithelial 
polarity, which contributes to tumorigenesis (Martin­Belmonte 
and Perez­Moreno, 2012).
Attenuated AMPK­mediated signaling could also be in­
volved in the increased metastatic potential of LKB1­deficient 
cancers. Loss of polarity not only contributes to tumorigenesis 
but also equips cancer cells with a morphology fit for invasion of 
surrounding tissues and dissemination to distant organs. The in­
creased abundance of HIF1, in addition to metabolic rewiring, 
transcriptionally activates programs involved in epithelial­to­
mesenchymal transition (EMT), matrix remodeling, and growth 
factor signaling that promote cell migration, local invasion, and 
dissemination (Lu and Kang, 2010). However, AMPK phos­
phorylates the microtubule plus­end­tracking protein CLIP­170 
to support microtubule dynamics and cell migration (Nakano 
et al., 2010). It is not known to what extent changes in these 
LKB1­AMPK–regulated processes contribute to metastasis of 
LKB1­deficient tumors. In melanoma and lung cancer where 
genetic mouse studies implicate LKB1 in metastasis suppres­
sion, the relevant LKB1 substrate is unidentified, but in both 
cases expansion of a CD24+ highly metastatic cell population is 
observed (Ji et al., 2007; Liu et al., 2012).
The work by Chan et al. adds a new function to LKB1 
that may underlie its role as a metastasis suppressor. In several 
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melanoma cell models the authors test how depletion or recon­
stitution of LKB1 affects cell migration. The presence of LKB1 
limits cell migration on 2D and in 3D ECM substrates. Cells 
lacking LKB1 do not pause at ECM boundaries and migrate ran­
domly with respect to 2D or 3D ECM gradients, whereas chemo­
taxis is fully intact. Notably, LKB1 does not regulate signaling 
by the integrin family of ECM receptors, secretion of ECM­ 
degrading proteases, or formation of pro­invasive cell substratum 
contacts called invadopodia. The authors show that haptotaxis 
requires membrane­targeted, kinase­active LKB1. They use RNA 
interference and pharmacological inhibitors to exclude involve­
ment of AMPK and several other LKB1 substrates expressed 
in the melanoma cells. Instead, they establish that the microtubule 
affinity­regulating kinases (MARKs) are essential mediators of 
LKB1­dependent haptotaxis. MARKs are known to phosphorylate 
microtubule­associated proteins (MAPs), thereby destabilizing 
microtubules (Illenberger et al., 1996). However, strikingly, the 
LKB1­MARK–mediated haptotaxis identified by Chan et al. 
(2014) does not depend on MAP phosphorylation, nor does it 
require intact microtubules.
This work adds a new branch to the LKB1 signaling net­
work that may be specifically important for its role as a metastasis 
suppressor. Future studies will have to unravel how LKB1­
MARK signaling controls haptotaxis, if not through MAP­ 
mediated control of microtubule dynamics. What is the relevant 
MARK substrate for LKB1­controlled haptotaxis? Moreover, as 
is the case for most LKB1­controlled processes, it is unknown 
to what extent these findings are context dependent. Is the role 
for LKB1 in haptotaxis specific for melanoma cells? How is 
it affected by the repertoire of mutated oncogenes and tumor 
suppressors in a given cancer? And, perhaps most urgent, is this 
pathway really responsible for the strong metastatic potential 
of LKB1­deficient melanomas? The authors provide evidence 
that MARKs limit melanoma cell invasion in 3D ECM sub­
strates, but the question of whether LKB1­MARK–mediated 
haptotaxis represents a metastasis­suppressing process remains 
to be answered.
Figure 1. Summary of known and predicted tumor- and metastasis-suppressing functions of LKB1. (i) Pathways restricted by LKB1 activity are indicated in 
gray, and pathways promoted by LKB1 are indicated in black. (ii) Using the same color scheme as in i, the effects of LKB1 loss in cancer cells are shown. 
The resulting known and predicted consequences of LKB1 loss for aspects of tumorigenesis and metastasis are indicated in blue. Note that only a limited 
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